<Anchor>

Yesterday (19th), it was news that a company in the United States is developing a corona19 vaccine and antibodies were formed in the first phase of clinical trials.

It's good news for you, but medical journalist Cho Dong-chan covered what process people actually need to take before getting vaccinated.

<Reporter> If you get a

virus or get a vaccine, there are several types of antibodies.

There are good antibodies that interfere with the cell's penetration into the virus, but some have no role or, rather, bad antibodies that help the virus penetrate cells well.

Of these, good antibodies that block viruses are called neutralizing antibodies, but the effectiveness of the vaccine depends on how many neutralizing antibodies are produced.

U.S. Modena vaccines confirmed the first neutralized antibodies in 8 out of 45 participants.

The vaccine is considered successful as the first step in a clinical trial because it has proven that it can block the Corona19 virus.

However, the amount of neutralizing antibodies has not been determined enough, and safety has not been verified.

In some cases, when a person who is vaccinated is actually exposed to a virus, more bad antibodies are produced than good neutralizing antibodies, and dengue fever vaccine has been banned for this reason.

[Song Man-gi / Deputy Director, International Vaccine Research Institute: Safety has not been verified. Later, commercialization still seems distant, as it is actually necessary to prove the safety when a virus is actually infected.]

Subsequent clinical trials will ensure that sufficient neutralizing antibodies are made and that there are no side effects that make the virus more prone to commercialization.